A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse

Journal of Clinical Psychopharmacology

Volumn 23, Issue 6, 2003, Pages 582-594

  Beasley Jr , Charles M ^a   Sutton, Virginia K ^a   Hamilton, Susan H ^a   Walker, Daniel J ^a   Dossenbach, Martin ^a   Taylor, Cindy C ^a   Alaka, Karla J ^a   Bykowski, Deborah ^a   Tollefson, Gary D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE MESILATE; BIPERIDEN; OLANZAPINE; TRIHEXYPHENIDYL;

ADULT; AKATHISIA; ANOREXIA; ANXIETY; APATHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HALLUCINATION; HOSTILITY; HUMAN; INSOMNIA; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PARANOIA; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAPSE; RISK BENEFIT ANALYSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; STATISTICAL ANALYSIS; TARDIVE DYSKINESIA; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RECURRENCE; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 0344033647     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000095348.32154.ec     Document Type: Article

References (41)

1. Marder SR. Antipsychotic drugs and relapse prevention. Schizophr Res. 1999;35(suppl):S87-S92.
2. Marder SR, Van Putten T, Mintz J, et al. Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry. 1984;41:1025-1029.
3. Kane JM, Woerner M, Weinhold P, et al. Incidence of tardive dyskinesia: five-year data from a prospective study. Psychopharmacol Bull. 1984;20:387-389.
4. Smith SM, O'Keane V, Murray R: Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry. 2002;181:49-55.
5. Collaborative Working Group on Clinical Trial Evaluations. Evaluating the effects of antipsychotics on cognition in schizophrenia. J Clin Psychiatry. 1998;59(suppl 12):35-40.
6. Kane JM, Rifkin A, Woerner M, et al. Low-dose neuroleptic treatment of outpatient schizophrenics. 1. Preliminary results for relapse rates. Arch Gen Psychiatry. 1983;40:893-896.
7. Marder SR, VanPutten T, Mintz J: Low- and conventional-dose maintenance therapy with fluphenazine decanoate: two-year outcome. Arch Gen Psychiatry. 1987;44:513-521.
8. Hogarty GE, McEvoy JP, Munetz M, et al. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study. Arch Gen Psychiatry. 1988;45:797-805.
9. Johnson DA, Ludlow JM, Street K, et al. Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised outpatients with schizophrenia. Br J Psychiatry. 1987;151:634-638.
10. Dellva MA, Tran PV, Tollefson GD, et al. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatr Serv. 1997;48:1571-1577.
11. Tran PV, Dellva MA, Tollefson GD, et al. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry. 1998;172:499-505.
12. Csernansky JG, Mahmoud R, Brenner R: A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346:16-22.
13. Arato M, O'Connor R, Meltzer HY: A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol. 2002;17:207-215.
14. Hirsch SR, Kissling W, Bauml J, et al. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry. 2002;63:516-523.
15. Kujawa M, Saha AR, Ingenito GG, et al. Aripiprazole for long-term maintenance treatment of schizophrenia. Intl J Neuropsychopharmacol. 2002;5(suppl 1):S186-S187.
16. Carson WH, Pigott TA, Saha AR, et al. Aripiprazole vs. placebo in the treatment of chronic schizophrenia. Int J Neuropsychopharmacol. 2002;5(suppl 1):S187.
17. Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996;14:111-123.
18. Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol. 1997;7:125-137
19. Greenhouse JB, Stangl D, Kupfer DJ, et al. Methodologic issues in maintenance therapy clinical trials. Arch Gen Psychiatry. 1991;48:313-318.
20. Gilbert P, Harris J, McAdams LA, et al. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry. 1995;52:173-188.
21. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med. 2000;133:455-463.
22. Rothman KJ, Michels KB. The continuing unethical use of placebo controls. N Engl J Med. 1994;331:394-398.
23. Freedman B, Glass KC, Weijer C. Placebo orthodoxy in clinical research. II. Ethical, legal, and regulatory myths. J Law Med Ethics. 1996;24:252-259.
24. Curson DA, Hirsch SR, Platt SD, et al. Does short term placebo treatment of chronic schizophrenia produce long term harm? BMJ. 2002;293:726-728.
25. Khan A, Khan SR, Leventhal RM, et al. Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the Food and Drug Administration database. Am J Psychiatry. 2001;158:1449-1454.
26. Storosum JG, van Zwieten BJ, Wohlfarth T, et al. Suicide risk in placebo vs. active treatment in placebo-controlled trials for schizophrenia. Arch Gen Psychiatry. 2003;60:365-368.
27. Storosum JG, van Zwieten BJ, van den Brink W, et al. Suicide risk in placebo-controlled studies of major depression. Am J Psychiatry. 2001;158:1271-1275.
28. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Publication ADM 76-338 ed. Bethesda, MD: US Department of Health, Education, and Welfare; 1976.
29. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
30. Kane J, Honigfeld G, Singer J, et al. Clozapine for treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
31. Kay S, Opler L, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems; 1986.
32. Whitehead J. The design and analysis of sequential clinical trials, second edition. West Sussex, England: Wiley; 1997.
33. Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10:388-398.
34. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. 1970;212:S11-S19.
35. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
36. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Publication ADM 76-338 ed. Bethesda, MD: US Department of Health, Education, and Welfare; 1976.
37. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia [letter]. Arch Gen Psychiatry. 1982;39:486-487.
38. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549-556.
39. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70:659-663.
40. SAS Institute SAS/STAT User's Guide. 4th Edition, 6th Version. Cary, NC: SAS Institute; 1990.
41. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154:457-465.